| Market revenue in 2024 | USD 1,585.5 million |
| Market revenue in 2030 | USD 3,797.3 million |
| Growth rate | 15.9% (CAGR from 2025 to 2030) |
| Largest segment | Topical |
| Fastest growing segment | Transdermal |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Topical, Transdermal |
| Key market players worldwide | The Lubrizol Corp, Cambrex, Contract Pharmaceuticals Limited, Bora Pharmaceuticals, Ascendia Pharmaceuticals, Pierre Fabre, Piramal Pharma Solutions, DPT Laboratories, LGM Pharma, Pace Analytical Services |
Publish Date: Dec 09, 2024
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| The Lubrizol Corp | View profile | 5001-10000 | Wickliffe, Ohio, United States, North America | www.lubrizol.com/ |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| Pace Analytical Services | View profile | 11-50 | Woburn, Massachusetts, United States, North America | www.pacelifesciences.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
| Pierre Fabre | View profile | 10001+ | Castres-gironde, Aquitaine, France, Europe | www.pierre-fabre.com |
| Contract Pharmaceuticals Limited | View profile | 251-500 | Mississauga, Ontario, Canada, North America | www.cplltd.com |
| Bora Pharmaceuticals | View profile | 501-1000 | Taipei, T'ai-pei, Taiwan, Asia | www.bora-corp.com/ |
| Ascendia Pharmaceuticals | View profile | 101-250 | North Brunswick, New Jersey, United States, North America | ascendiapharma.com/ |
| DPT Laboratories | View profile | 1001-5000 | San Antonio, Texas, United States, North America | www.dptlabs.com |
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | lgmpharma.com/ |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Semi-Solid Dosage CDMO Market Outlook will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 101.8% in 2024.
Horizon Databook has segmented the Japan semi-solid dosage cdmo market based on topical, transdermal covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Semi-Solid Dosage CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Semi-Solid Dosage CDMO Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
